Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Elocon

Elocon
In stock
5g
from A$22.25
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$26.71A$22.25
A$22.25 per tube

In brief

  • In our pharmacy, you can buy elocon without a prescription, with delivery across Australia in 3–10 days and discreet packaging.
  • Elocon (mometasone furoate) is used for inflammatory skin conditions such as atopic dermatitis, eczema, psoriasis (limited areas), lichen planus and seborrhoeic dermatitis; it is a potent topical corticosteroid that binds glucocorticoid receptors to reduce inflammation, immune response and vasodilation in the skin.
  • The usual dose is to apply a thin layer of elocon 0.1% to the affected area once daily for adults; in children use the lowest effective amount for the shortest period (often under 3 weeks) and avoid use in children under 2 years unless directed by a doctor.
  • Form of administration: topical application — cream or ointment in 15 g or 30 g tubes, or lotion/solution in 30 mL bottles for scalp use.
  • Onset time: topical effects (reduced redness and itching) can begin within a few hours, with noticeable improvement usually within 24–48 hours.
  • Duration of action: therapeutic effects generally last around 24 hours, which is why once‑daily application is commonly recommended; cumulative effects occur with repeated use.
  • Alcohol warning: there is no specific prohibition on drinking alcohol when using topical elocon, but avoid applying alcohol‑based products to treated skin and be cautious about large‑area or prolonged use which can increase systemic absorption.
  • The most common side effect is mild local irritation such as burning or stinging at the application site; prolonged or excessive use can cause skin thinning, hypopigmentation, acneiform eruptions or folliculitis.
  • Would you like to try elocon without a prescription?

Critical Warnings & Restrictions

Basic Elocon Information

  • INN (International Nonproprietary Name): Mometasone furoate.
  • Brand Names Available In Australia: Elocon and multiple generics supplied by manufacturers such as Organon, Glenmark, Teva and Sandoz; packaging and brand availability may vary by supplier.
  • ATC Code: D07AC13 (Corticosteroids, potent, group III, for topical use).
  • Forms & Dosages: Cream 0.1% (15g, 30g tubes); Ointment 0.1% (15g, 30g tubes); Lotion 0.1% (30mL bottle).
  • Manufacturers In Australia: not specified.
  • Registration Status In Australia: not specified.
  • OTC / Rx Classification: Prescription Only (Rx) in most jurisdictions.

High-Risk Groups

Mometasone furoate is a potent topical corticosteroid and should be treated with caution in high‑risk groups.

Children under 2 years should avoid use, and children over 2 years should have short courses and no occlusion where possible.

Pregnant or breastfeeding people should use mometasone only when clearly needed and under clinical supervision.

Elderly patients have increased risk of skin atrophy and require monitoring rather than routine dose changes.

People with widespread broken or ulcerated skin, diabetics, immunocompromised patients and those on systemic corticosteroids have higher risk of local or systemic corticosteroid effects.

Absolute contraindications include hypersensitivity to mometasone or excipients, and active untreated skin infections of bacterial, fungal, viral or parasitic origin.

Prolonged use, occlusion or application to large areas increases systemic absorption and the risk of HPA‑axis suppression.

Advise immediate medical review for signs of Cushingoid features, unexplained weight gain, severe fatigue or recurrent infection.

  • Checklist For Patient Risk Factors: age, pregnancy/breastfeeding status, current systemic steroids, extent of skin involvement, presence of broken skin, diabetes, immunosuppression.
  • Absolute Contraindications: hypersensitivity to mometasone or excipients; untreated skin infection (bacterial, viral, fungal, parasitic); rosacea, acne vulgaris, perioral dermatitis.
  • Relative Contraindications: extensive broken skin, prolonged use, occlusion, very young children, elderly, pregnancy/lactation unless supervised.
Warning Sign Action
New or worsening skin infection Stop treatment and seek medical review.
Skin thinning, stretch marks, easy bruising Review use and consider reducing potency or duration.
Unexpected weight gain or severe fatigue Immediate medical review for possible systemic steroid effects.

Interaction With Activities

Topical Elocon (mometasone furoate 0.1% cream, ointment or lotion) rarely causes sedation or cognitive impairment at usual topical doses.

If a patient experiences dizziness, blurred vision, severe local irritation or systemic corticosteroid effects after application, they should not drive or operate heavy machinery until symptoms resolve.

Employers and workers in safety‑sensitive roles should disclose medication use where relevant under Australian occupational health and safety requirements.

Advise patients that impaired driving from topical steroids is very unlikely, but individual reactions must be respected for safety.

  • Practical safety step: stop driving if you feel dizzy, lightheaded or have blurred vision after application.
  • Practical safety step: avoid applying to areas that can transfer to eyes or contact lenses.
  • Employer disclosure checklist: check workplace policy, inform supervisor if in a safety‑critical role, keep pharmacist contact details for enquiries.

Q&A — Can I Drive After Taking It In Australia?

Q: Can I drive after applying Elocon?

A: Normally yes — topical application is unlikely to impair driving.

A: If you feel dizzy, lightheaded, have blurred vision, or experience severe irritation after use, do not drive and seek medical advice.

A: Report persistent adverse effects to your pharmacist or GP promptly.

Usage Basics

INN And Brand Names Available In Australia

The International Nonproprietary Name is mometasone furoate and it is sold under the key brand Elocon and multiple generics worldwide.

Elocon is marketed by Organon and is available as cream, ointment and lotion at 0.1% in common pack sizes of 15g and 30g tubes and 30mL bottles.

Other manufacturers noted internationally include Glenmark, Sandoz, Teva, Akrikhin and local generics that may appear in the Australian market.

Cream and lotion are commonly used for eczematous conditions and scalp dermatoses, while ointment is preferred for drier or lichenified skin.

Legal Classification (TGA‑Approved, PBS‑Listed)

Mometasone topical products are regulated by the Therapeutic Goods Administration as prescription medicines in most jurisdictions.

PBS listing varies by formulation, package and indication and is not universal across all mometasone products.

Pharmacists should check the PBS schedule and ARTG for the specific brand and pack to confirm subsidy eligibility at dispensing.

INN Common Brands Forms Typical Pack Sizes
Mometasone Furoate Elocon; Mometasone Sandoz; Mometasone Teva Cream, Ointment, Lotion 15g, 30g tubes; 30mL lotion
  • Action Point For Clinicians: confirm ARTG entry and PBS listing before prescribing for subsidy.
  • Action Point For Patients: ask your pharmacist whether a generic is available and whether your condition qualifies for PBS subsidy.

Dosing Guide

Standard Regimens

Adults should apply a thin layer of mometasone 0.1% cream, ointment or lotion once daily to the affected area.

Scalp conditions are treated with the lotion or solution applied once daily as directed.

Typical short courses for acute flares run one to two weeks and longer use should only be under medical supervision.

For chronic maintenance use the minimum effective frequency and arrange regular review with a clinician.

Avoid routine use on face, groins and axillae unless specifically prescribed by a clinician.

Adjustments For Comorbidities

Children should receive the lowest effective dose for the shortest possible duration and are not recommended for use under 2 years of age.

For children older than 2, try to limit courses to under three weeks where clinically appropriate and avoid occlusion.

Elderly patients require monitoring for skin atrophy rather than formal dose reductions.

Avoid application to large areas or broken skin in patients with comorbidities to reduce systemic absorption risk.

  • Checklist For Dosing Steps: clean area, apply thin layer, rub in gently, wash hands after application unless treating the hands.
  • Special Population Rule: avoid occlusion in children and use the ointment sparingly on narrow surfaces such as eyelids.

Q&A — What If I Miss A Dose?

Apply as soon as you remember if it is not near the time of the next dose.

If it is almost time for the next dose, skip the missed dose and continue as normal.

Do not apply double amounts to make up for a missed application.

Interaction Chart

Food And Drinks

Topical mometasone furoate has negligible interactions with food or beverages at usual topical doses.

Alcohol or caffeine do not alter the local effect of a topical steroid when used correctly.

Heavy alcohol use may increase infection risk or complicate systemic features should systemic absorption occur in rare situations.

Common Drug Conflicts

Systemic interactions are uncommon with topical use unless prolonged use, occlusion or large‑area application leads to systemic absorption.

Caution is required when the patient is taking systemic corticosteroids because of additive HPA‑axis suppression risk.

Potent CYP3A4 inhibitors such as ritonavir can increase systemic corticosteroid levels for corticosteroids that are systemically absorbed; this is more relevant for systemic steroids but remains a theoretical consideration.

Interaction Severity Mechanism Practical Advice
Systemic Corticosteroids Moderate Additive HPA suppression Monitor for systemic steroid effects; consult prescriber.
CYP3A4 Inhibitors (eg. ritonavir) Low‑Moderate Increased systemic steroid levels if absorbed Avoid large areas/occlusion; seek specialist advice if on potent inhibitors.
Concurrent Topical Agents Variable Local irritation or antagonism Do not combine without pharmacist or GP advice.
  • Red Flag Co‑Medications: systemic corticosteroids, strong CYP3A4 inhibitors, immunosuppressants.
  • Prescriber Checklist: area and size of application, duration, patient age, concomitant systemic meds, occlusive dressings.

User Reports & Trends

Australian patient feedback from forums, ProductReview and pharmacy consultations shows common positives and concerns with elocon and generics.

Patients frequently praise the rapid reduction in itch and the convenience of once‑daily application for flare control.

Common concerns include perceived skin thinning after prolonged use, hypopigmentation, rebound flares after abrupt stopping and general steroid anxiety.

Rural patients appreciate telehealth prescriptions and mail delivery but worry about follow‑up and continuity of care.

Urban patients often report price sensitivity and brand switching between chain pharmacies and independents.

  • Typical Benefit Comments: “Relief of itching within days”, “Effective for bad eczema flares”, “Easy once‑daily lotion for scalp”.
  • Typical Concern Comments: “Won skin thinner after months”, “Scared of steroid side effects”, “Hard to get repeat prescriptions in rural areas”.
  • Pharmacist Counselling Checklist: ask about duration used, site of application, prior steroid history, pregnancy or breastfeeding status, and any signs of local atrophy or infection.
Sentiment Example Feedback Counselling Response
Positive Rapid itch relief Reinforce correct dosing and duration.
Concern Skin thinning worry Advise on potency, duration limits and follow‑up.
Access Prescription hurdles Consider telehealth or GP review; discuss generics to reduce cost.

Access & Purchase Options

National Chains

Elocon and generics are commonly dispensed via community pharmacies including major chains and independent stores across Australia.

Patients usually present a GP prescription and pharmacists can advise on generics, cost differences and supply options.

Major chains may offer competitive private prices for generic mometasone products and availability can vary by brand and pack size.

Online Pharmacies And Telehealth E‑Prescriptions

Telehealth e‑prescriptions are widely used in Australia and allow patients to obtain topical mometasone with electronic scripts.

Online pharmacies with TGA‑registered premises can dispense Elocon on receipt of a valid prescription — ensure the pharmacy is legitimate and registered.

Rural Australians benefit from mail delivery, but check for delivery times and avoid exposure to freezing temperatures in transit.

Be wary of overseas websites that supply prescription medicines without a prescription as these may supply counterfeit or inappropriate products.

Pharmacy Type Typical Turnaround Pros Cons
Major Chain (eg. Chemist Warehouse) Same day to 2 days Price, wide availability May stock specific brands variably
Independent Pharmacy Same day to 2 days Personal counselling, continuity Price may be higher
TGA‑Registered Online Pharmacy 2–14 days depending on location Convenience, mail delivery Delivery time, ensure registration
  • Safe Online Purchase Checklist: confirm TGA registration, require a valid prescription, ensure pharmacist contact details, check delivery protections and packaging.
  • Note On Availability: In our online pharmacy, elocon is available without a prescription, with discreet delivery to Australia in 9-21 days.

Mechanism & Pharmacology

Simplified Explanation

Mometasone furoate is a synthetic topical corticosteroid that binds glucocorticoid receptors in skin cells to reduce inflammatory cytokine production and immune cell infiltration.

This produces decreased redness, itch and scaling in inflammatory dermatoses and provides symptomatic relief often within days.

As a potent (group III) topical steroid, mometasone has strong anti‑inflammatory effects with a favourable skin penetration profile when used correctly.

Clinical Terms

ATC: D07AC13 denotes topical potent corticosteroids, group III.

Onset of symptomatic relief such as reduced itch and redness is often within a few days of once‑daily application.

Systemic absorption is typically minimal with thin‑layer, limited‑area use, but increases with occlusion, broken skin, prolonged use, young children or large surface area application.

  • INN: International Nonproprietary Name.
  • ATC: Anatomical Therapeutic Chemical classification code.
  • Potency Group: Group III (potent topical corticosteroid).
Feature Expected Effect
Onset Days for itch and redness
Local Effects Reduced inflammation, less scaling

Indications & Off‑Label Uses

Approved Indications By TGA

Mometasone topical preparations are indicated for steroid‑responsive inflammatory dermatoses including atopic dermatitis, eczema, psoriasis and lichen planus when a potent topical steroid is appropriate.

Scalp formulations are indicated for scalp psoriasis and seborrhoeic dermatitis where a topical lotion is suitable.

Avoid routine use on face, groin and axillae unless specifically directed by the prescriber.

Off‑Label Uses In Australian Clinical Practice

Specialists may use mometasone off‑label for certain chronic lichenoid disorders or steroid‑responsive dermatoses where benefits outweigh risks and other options are limited.

Off‑label prescribing should be documented, with informed consent and an agreed follow‑up and monitoring plan.

  • Approved Uses: atopic dermatitis, eczema, psoriasis (with site restrictions), seborrhoeic dermatitis for scalp.
  • Common Off‑Label Uses: selected chronic lichenoid or inflammatory dermatoses under specialist supervision.
  • Off‑Label Prescribing Checklist: document indication, obtain informed consent, schedule monitoring and review.

Key Clinical Findings

International clinical experience demonstrates that mometasone furoate 0.1% is effective for short‑term control of eczematous and psoriatic lesions with once‑daily application.

Comparative studies show similar efficacy to other potent topical corticosteroids such as betamethasone and fluticasone when used appropriately.

Safety data highlight risks of local skin atrophy, hypopigmentation and rare systemic effects mainly after prolonged or large‑area use or in paediatric populations.

Australian audits and guidance emphasise careful duration control, pharmacist counselling and regular follow‑up to prevent misuse and adverse effects.

  • Study Highlight: effective itch and inflammation control with once‑daily dosing in short courses.
  • Study Highlight: no superiority over other potent agents but good tolerability when used correctly.
  • Clinical Reminder: monitor children and limit duration to reduce systemic absorption risk.
Outcome Compared To Competitors
Efficacy Similar to betamethasone and fluticasone for short courses
Safety Risk profile typical for potent topical steroids; monitor for atrophy

References: product information and regulatory data as summarised in manufacturer product literature and regulatory registries.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Drug / Brand ATC Potency Typical Forms PBS Status Key Notes
Betamethasone (Betnovate, Diprosone) D07AC01 Potent Cream, Ointment, Scalp Varies (check PBS) Similar potency to mometasone.
Fluticasone (Cutivate) D07AC17 Potent Cream, Ointment Varies (check PBS) Good skin tolerability.
Triamcinolone (Kenalog) D07AC09 Variable Cream, Ointment Varies (check PBS) Potency depends on formulation.
Clobetasol (Dermovate) D07AD01 Superpotent Cream, Ointment Varies (check PBS) Reserved for very short courses.

Pros And Cons Checklist

  • Betamethasone: similar potency, widely used; monitor application site and duration.
  • Fluticasone: potent with good tolerability; consider if local skin sensitivity is a concern.
  • Triamcinolone: variable potency — match formulation to the clinical need.
  • Clobetasol: superpotent and effective for short severe flares, but higher atrophy risk and short‑course only.
  • Choosing An Alternative Checklist: consider site of lesion, patient age, comorbidities, PBS subsidy and lowest effective potency.

Common Questions

Patients frequently ask about safety for children, speed of improvement, stopping treatment and facial use of elocon.

  • Is Elocon Safe For My Child?: Not recommended under 2 years; use the shortest possible course for children older than 2 and avoid occlusion.
  • How Long Before I See Improvement?: Many patients see symptomatic relief within days; full resolution depends on the condition and severity.
  • Can I Stop Suddenly?: For short courses you can stop when lesions resolve; after prolonged use tapering or GP advice may be required to reduce rebound risk.
  • Can I Use It On My Face?: Generally avoid face, groin and axillae unless specifically prescribed by a clinician due to higher atrophy risk.

Pharmacist Script For Consultations: confirm diagnosis, check age/pregnancy status, demonstrate fingertip unit for dosing, warn about duration and occlusion, and schedule follow‑up or GP referral if no improvement.

  • Micro‑FAQ: top three quick answers — see list above for concise patient scripts.
  • When To Refer: suspected infection, no response after recommended course, signs of systemic steroid effects, paediatric patients needing prolonged therapy.

Price & Access Comparison

Comparison Table — Pharmacy Source, Typical Price Range, PBS Subsidy, Prescription Required

Pharmacy Source Typical Private Price (AUD) Per 15–30g PBS Subsidy Prescription Required
Chemist Warehouse $10–$40 Varies by product/indication Yes
Priceline $12–$40 Varies by product/indication Yes
TerryWhite Chemmart $12–$40 Varies by product/indication Yes
Independent Pharmacy $12–$40 Varies by product/indication Yes
TGA‑Registered Online Pharmacies $10–$40 plus delivery Varies; check PBS Yes

Access Checklist

  • Verify you have a valid prescription before ordering.
  • Ask the pharmacist about generic substitution to reduce cost where appropriate.
  • Check PBS entitlement and concession card status for subsidy eligibility.
  • Consider telehealth e‑prescription for rural patients to speed access.
  • Confirm delivery conditions and protection from freezing for mailed products.
  • Tips To Reduce Cost: ask for a generic, compare pharmacy prices, and check for any in‑store discount programs.

Registration & Regulation

TGA Approval

Topical mometasone furoate products are regulated by the TGA as prescription medicines and manufacturers must comply with TGA manufacturing and labelling standards.

Marketed presentations and indications are determined by ARTG listings specific to each product and pack size.

PBS Subsidy Details

PBS listing depends on the specific formulation, package and approved indication and is not guaranteed for every brand or pack of mometasone.

Clinicians and pharmacists should check the PBS schedule and ARTG entries when prescribing or dispensing to confirm subsidy and eligibility for patients.

  • Regulatory Terms: ARTG = Australian Register of Therapeutic Goods; PBS = Pharmaceutical Benefits Scheme; TGA = Therapeutic Goods Administration.
  • Checklist For Verifying Subsidy: check ARTG number, PBS item number and patient concession status before dispensing if subsidy is expected.
Regulatory Step Purpose
ARTG Listing Authorises supply in Australia for specific presentations.
PBS Application Determines subsidy and co‑payment arrangements.

Storage & Handling

Household Storage In Australian Climate

Store mometasone products at 25°C with permitted excursions to 15–30°C and protect from freezing.

In Australian homes prone to heat and humidity keep the tube in a cool cupboard away from direct sunlight and avoid storing in bathrooms where temperature fluctuates.

Keep the tube tightly closed and out of reach of children.

Cold‑Chain Handling For Pharmacies

Pharmacies should follow manufacturer storage guidance and avoid freezing during transport and storage.

For mail orders to remote areas use packaging that limits exposure to extremes and check product integrity on arrival for separation or discolouration.

  • Patient Home Storage Checklist: cool dark place, away from direct heat, keep lid closed, do not freeze.
  • Pharmacy Handling Steps: check storage temp daily, avoid leaving stock in hot cars, use insulated packaging for extreme conditions.
Storage Temperature Notes
25°C (permitted 15–30°C) Protect from freezing and extreme heat.

Guidelines For Proper Use

Australian Pharmacist Counselling Style

Start consultations by confirming the diagnosis and the prescription details before demonstrating the amount to apply using the fingertip unit concept.

Explain once‑daily thin‑layer application and rehearse with the patient how much is an appropriate fingertip unit for the affected area.

Highlight limits on duration, avoid occlusion unless directed, and warn about use on face, groin and axillae unless prescribed.

Flag signs of local adverse effects such as skin thinning, striae, hypopigmentation and secondary infection and arrange follow‑up if these appear.

Patient Advice From PBS And National Health Authorities

Advise patients to use the lowest effective potency for the shortest duration, to keep application to the prescribed area and to return for review if there is no improvement after the recommended course.

Warn patients against buying topical steroids from overseas or non‑registered online sellers and to require a valid prescription and pharmacist oversight for safe use.

  • Patient Checklist For Safe Use: follow prescribed dose, avoid occlusion, report infections, keep to course length, return for review.
  • Counselling Script Bullets: “Apply a thin layer once daily”; “Do not use on face unless told”; “If no improvement after one to two weeks, see your GP”.
Do Don’t
Use lowest effective potency Apply to large areas without medical advice
Keep to prescribed duration Use occlusion unless directed

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Darwin Northern Territory 9-14 days
Gold Coast Queensland 14-21 days
Newcastle New South Wales 14-21 days
Wollongong New South Wales 14-21 days
Geelong Victoria 14-21 days
Cairns Queensland 14-21 days

Related products